These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35318785)

  • 1. Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy.
    Schorling DC; Kölbel H; Hentschel A; Pechmann A; Meyer N; Wirth B; Rombo R; ; Sickmann A; Kirschner J; Schara-Schmidt U; Lochmüller H; Roos A
    Eur J Neurol; 2022 Jul; 29(7):2084-2096. PubMed ID: 35318785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric spinal muscular atrophy.
    Dobelmann V; Roos A; Hentschel A; Della Marina A; Leo M; Schmitt LI; Maggi L; Schara-Schmidt U; Hagenacker T; Ruck T; Kölbel H
    J Neurol; 2024 Oct; 271(10):7000-7011. PubMed ID: 39240344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1-3 patients treated with nusinersen.
    Šimić G; Vukić V; Babić M; Banović M; Berečić I; Španić E; Zubčić K; Golubić AT; Barišić Kutija M; Merkler Šorgić A; Vogrinc Ž; Lehman I; Hof PR; Sertić J; Barišić N
    CNS Neurosci Ther; 2024 Mar; 30(3):e14051. PubMed ID: 36513962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of LARGE1 abundance in patients and a mouse model of 5q-associated spinal muscular atrophy.
    Roos A; Schmitt LI; Hansmann C; Hezel S; Salmanian S; Hentschel A; Meyer N; Marina AD; Kölbel H; Kleinschnitz C; Schara-Schmidt U; Leo M; Hagenacker T
    Acta Neuropathol; 2024 Mar; 147(1):53. PubMed ID: 38470509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy.
    Kessler T; Latzer P; Schmid D; Warnken U; Saffari A; Ziegler A; Kollmer J; Möhlenbruch M; Ulfert C; Herweh C; Wildemann B; Wick W; Weiler M
    J Neurochem; 2020 Jun; 153(5):650-661. PubMed ID: 31903607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy.
    Panicucci C; Sahin E; Bartolucci M; Casalini S; Brolatti N; Pedemonte M; Baratto S; Pintus S; Principi E; D'Amico A; Pane M; Sframeli M; Messina S; Albamonte E; Sansone VA; Mercuri E; Bertini E; Sezerman U; Petretto A; Bruno C
    Cell Mol Life Sci; 2024 Sep; 81(1):393. PubMed ID: 39254732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The light at the end of the tunnel gets vivid for spinal muscular atrophy: An Editorial Highlight for "Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy" on page 650.
    Dutta D; Chandra G; Mohanakumar KP
    J Neurochem; 2020 Jun; 153(5):545-548. PubMed ID: 32128827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients.
    Faravelli I; Meneri M; Saccomanno D; Velardo D; Abati E; Gagliardi D; Parente V; Petrozzi L; Ronchi D; Stocchetti N; Calderini E; D'Angelo G; Chidini G; Prandi E; Ricci G; Siciliano G; Bresolin N; Comi GP; Corti S; Magri F; Govoni A
    J Cell Mol Med; 2020 Mar; 24(5):3034-3039. PubMed ID: 32032473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen.
    Trifunov S; Natera-de Benito D; Carrera-García L; Codina A; Expósito-Escudero J; Ortez C; Medina J; Torres Alcala S; Bernal S; Alias L; Badosa C; Balsells S; Alcolea D; Nascimento A; Jimenez-Mallebrera C
    J Neuromuscul Dis; 2023; 10(4):653-665. PubMed ID: 37038823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen.
    Rich KA; Fox A; Yalvac M; Heintzman S; Tellez M; Bartlett A; Severyn S; Linsenmayer M; Kelly K; Reynolds J; Sterling GB; Weaver T; Rajneesh K; Pino MG; Arnold WD; Elsheikh B; Kolb SJ
    J Neuromuscul Dis; 2022; 9(1):111-119. PubMed ID: 34776417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen.
    Seo G; Kim S; Byun JC; Kwon S; Lee YJ
    Brain Dev; 2023 Nov; 45(10):554-563. PubMed ID: 37541812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen.
    Totzeck A; Stolte B; Kizina K; Bolz S; Schlag M; Thimm A; Kleinschnitz C; Hagenacker T
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
    Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL
    Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of cerebrospinal fluid biomarkers in pediatric patients with spinal muscular atrophy.
    Kobayashi Y; Ishikawa N; Tateishi Y; Izumo H; Eto S; Eguchi Y; Okada S
    Brain Dev; 2023 Jan; 45(1):2-7. PubMed ID: 36210235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen.
    Johannsen J; Weiss D; Daubmann A; Schmitz L; Denecke J
    J Cell Mol Med; 2021 Sep; 25(17):8419-8431. PubMed ID: 34312963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients.
    Magen I; Aharoni S; Yacovzada NS; Tokatly Latzer I; Alves CRR; Sagi L; Fattal-Valevski A; Swoboda KJ; Katz J; Bruckheimer E; Nevo Y; Hornstein E
    Eur J Neurol; 2022 Aug; 29(8):2420-2430. PubMed ID: 35510740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is cerebrospinal fluid amyloid-β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients?
    Introna A; Milella G; D'Errico E; Fraddosio A; Scaglione G; Ucci M; Ruggieri M; Simone IL
    Muscle Nerve; 2021 Jun; 63(6):905-909. PubMed ID: 33660868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurodegeneration Biomarkers in Adult Spinal Muscular Atrophy (SMA) Patients Treated with Nusinersen.
    Andrés-Benito P; Vázquez-Costa JF; Ñungo Garzón NC; Colomina MJ; Marco C; González L; Terrafeta C; Domínguez R; Ferrer I; Povedano M
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.
    Wurster CD; Steinacker P; Günther R; Koch JC; Lingor P; Uzelac Z; Witzel S; Wollinsky K; Winter B; Osmanovic A; Schreiber-Katz O; Al Shweiki R; Ludolph AC; Petri S; Hermann A; Otto M;
    J Neurol; 2020 Jan; 267(1):36-44. PubMed ID: 31552549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.